-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bioventus (NYSE:BVS) Updates FY 2022 Earnings Guidance
Bioventus (NYSE:BVS) Updates FY 2022 Earnings Guidance
Bioventus (NYSE:BVS – Get Rating) issued an update on its FY 2022 earnings guidance on Friday morning. The company provided earnings per share guidance of $0.47-$0.57 for the period, compared to the consensus earnings per share estimate of $0.65. The company issued revenue guidance of $547.50 million-$562.50 million, compared to the consensus revenue estimate of $552.13 million.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley upped their target price on Bioventus from $11.00 to $12.00 and gave the stock an overweight rating in a report on Friday, August 12th.
Get Bioventus alerts:Bioventus Stock Performance
Shares of BVS stock opened at $7.29 on Friday. The company has a market capitalization of $564.62 million, a P/E ratio of -21.76 and a beta of 2.07. The business's 50 day moving average is $7.97 and its two-hundred day moving average is $10.26. The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. Bioventus has a 12-month low of $6.30 and a 12-month high of $17.53.
Bioventus (NYSE:BVS – Get Rating) last issued its quarterly earnings results on Thursday, August 11th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). Bioventus had a positive return on equity of 10.35% and a negative net margin of 4.26%. The business had revenue of $140.33 million for the quarter, compared to analysts' expectations of $140.01 million. During the same quarter in the prior year, the company posted $0.16 EPS. Analysts expect that Bioventus will post 0.54 EPS for the current fiscal year.Hedge Funds Weigh In On Bioventus
A number of hedge funds have recently made changes to their positions in BVS. Jane Street Group LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $355,000. Ergoteles LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $327,000. Rhumbline Advisers increased its holdings in shares of Bioventus by 58.6% in the second quarter. Rhumbline Advisers now owns 44,717 shares of the company's stock valued at $305,000 after purchasing an additional 16,517 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Bioventus by 57.4% in the first quarter. MetLife Investment Management LLC now owns 18,975 shares of the company's stock valued at $268,000 after purchasing an additional 6,917 shares during the last quarter. Finally, Zebra Capital Management LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $254,000. Institutional investors and hedge funds own 44.62% of the company's stock.
About Bioventus
(Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Featured Stories
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
Bioventus (NYSE:BVS – Get Rating) issued an update on its FY 2022 earnings guidance on Friday morning. The company provided earnings per share guidance of $0.47-$0.57 for the period, compared to the consensus earnings per share estimate of $0.65. The company issued revenue guidance of $547.50 million-$562.50 million, compared to the consensus revenue estimate of $552.13 million.
Bioventus(NYSE：BVS-GET Rating)週五上午發佈了2022財年最新收益指引。該公司提供的季度每股收益指引為0.47美元至0.57美元，而市場普遍預期的每股收益為0.65美元。該公司發佈的收入指引為5.475億至5.625億美元，而普遍的收入預期為5.5213億美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, Morgan Stanley upped their target price on Bioventus from $11.00 to $12.00 and gave the stock an overweight rating in a report on Friday, August 12th.
另外，摩根士丹利在8月12日週五的一份報告中將Bioventus的目標價從11.00美元上調至12.00美元，並給予該股加碼評級。
Bioventus Stock Performance
Bioventus股票表現
Shares of BVS stock opened at $7.29 on Friday. The company has a market capitalization of $564.62 million, a P/E ratio of -21.76 and a beta of 2.07. The business's 50 day moving average is $7.97 and its two-hundred day moving average is $10.26. The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. Bioventus has a 12-month low of $6.30 and a 12-month high of $17.53.
上週五，BVS股票開盤報7.29美元。該公司市值為5.462億美元，市盈率為-21.76，貝塔係數為2.07。該業務的50日移動均線切入位在7.97美元，200日移動均線切入位在10.26美元。該公司的流動比率為1.39，速動比率為1.05，債務權益比率為0.68。Bioventus的12個月低點為6.30美元，12個月高位為17.53美元。
Hedge Funds Weigh In On Bioventus
對衝基金對Bioventus的看法
A number of hedge funds have recently made changes to their positions in BVS. Jane Street Group LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $355,000. Ergoteles LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $327,000. Rhumbline Advisers increased its holdings in shares of Bioventus by 58.6% in the second quarter. Rhumbline Advisers now owns 44,717 shares of the company's stock valued at $305,000 after purchasing an additional 16,517 shares during the last quarter. MetLife Investment Management LLC increased its holdings in shares of Bioventus by 57.4% in the first quarter. MetLife Investment Management LLC now owns 18,975 shares of the company's stock valued at $268,000 after purchasing an additional 6,917 shares during the last quarter. Finally, Zebra Capital Management LLC acquired a new stake in shares of Bioventus in the first quarter valued at approximately $254,000. Institutional investors and hedge funds own 44.62% of the company's stock.
一些對衝基金最近改變了他們在BVS的頭寸。簡街集團有限責任公司在第一季度收購了Bioventus的新股份，價值約35.5萬美元。Ergoeles LLC在第一季度收購了Bioventus的新股份，價值約327,000美元。Rhumbline Advisers在第二季度增持了Bioventus的股票58.6%。Rhumbline Advisers在上個季度又購買了16,517股後，現在擁有44,717股該公司股票，價值30.5萬美元。大都會人壽投資管理有限責任公司第一季度增持了57.4%的Bioventus股票。大都會人壽投資管理有限責任公司現在擁有18,975股該公司的股票，價值268,000美元，在上個季度又購買了6,917股。最後，斑馬資本管理有限責任公司在第一季度收購了Bioventus的新股份，價值約為254,000美元。機構投資者和對衝基金持有該公司44.62%的股票。
About Bioventus
關於Bioventus
(Get Rating)
(獲取評級)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Bioventus公司是一家醫療設備公司，專注於開發臨牀治療方法並將其商業化，這些治療方法在美國和國際上參與並增強了人體的自然癒合過程。該公司的產品組合包括疼痛治療，其中包括非手術關節疼痛注射療法，以及周圍神經刺激產品。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免費獲取StockNews.com關於Bioventus(BVS)的研究報告
- 隨着管理層重組，股市能否迅速反彈？
- MarketBeat：回顧中的一週8/29-9/2
- 霍梅爾在這些水平上看起來很便宜
- 露露檸檬將飆升至9月
- 耐克股票會被超賣，但仍被高估嗎？
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
收到《Bioventus Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bioventus和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧